EA199800014A1 - Способы снижения до минимума эффекта остеопороза - Google Patents
Способы снижения до минимума эффекта остеопорозаInfo
- Publication number
- EA199800014A1 EA199800014A1 EA199800014A EA199800014A EA199800014A1 EA 199800014 A1 EA199800014 A1 EA 199800014A1 EA 199800014 A EA199800014 A EA 199800014A EA 199800014 A EA199800014 A EA 199800014A EA 199800014 A1 EA199800014 A1 EA 199800014A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compound
- formula
- osteoporosis
- pyrrolidinyl
- alkyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Данное изобретение обеспечивает способ сведения к минимуму эффекта остеопороза в результате действия соединения формулы (I), где R является -CHCON(CH)-н-CHCHCHCHили -SO(CH)CFCF, или его фармацевтически пригодной соли, при этом указанное соединение формулы (I) вводят нуждающемуся в лечении млекопитающему, включая одновременное или последовательное введение указанному млекопитающему эффективного количества соединения формулы (II), где каждый Rнезависимо является -H, -OH, -O(C-C-алкилом), -OCOCH, -OCO(C-C-алкилом) или -OSO(C-C-алкилом); а Rявляется 1-пиперидинилом, 1-пирролидинилом, метил-1-пирролидинилом, диметил-1-пирролидинилом, 4-морфолино, диметиламино, диэтиламино или 1-гексаметилениминогруппой; или его фармацевтически приемлемой соли. Обеспечен также способ минимизации остеопороза, вызванного введением соединения формулы (I), включающий одновременное или последовательное введение костного анаболика. Обеспечены также фармацевтические композиции.Международная заявка была опубликована вместе с отчетом о международном поиске.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47111195A | 1995-06-06 | 1995-06-06 | |
| PCT/US1996/008810 WO1996039141A1 (en) | 1995-06-06 | 1996-06-05 | Methods for minimizing bone loss |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA199800014A1 true EA199800014A1 (ru) | 1998-06-25 |
Family
ID=23870302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA199800014A EA199800014A1 (ru) | 1995-06-06 | 1996-06-05 | Способы снижения до минимума эффекта остеопороза |
Country Status (27)
| Country | Link |
|---|---|
| EP (1) | EP0747056B1 (ru) |
| JP (1) | JP2001501907A (ru) |
| KR (1) | KR19990022497A (ru) |
| CN (1) | CN1239429A (ru) |
| AR (2) | AR003002A1 (ru) |
| AT (1) | ATE187643T1 (ru) |
| AU (1) | AU696927B2 (ru) |
| BR (1) | BR9608390A (ru) |
| CA (1) | CA2223174A1 (ru) |
| CO (1) | CO4700447A1 (ru) |
| CZ (1) | CZ383097A3 (ru) |
| DE (1) | DE69605600T2 (ru) |
| DK (1) | DK0747056T3 (ru) |
| EA (1) | EA199800014A1 (ru) |
| ES (1) | ES2142545T3 (ru) |
| GR (1) | GR3032863T3 (ru) |
| HU (1) | HUP9900854A3 (ru) |
| IL (1) | IL118573A (ru) |
| NO (1) | NO975560L (ru) |
| PE (1) | PE2298A1 (ru) |
| PL (1) | PL323941A1 (ru) |
| PT (1) | PT747056E (ru) |
| SI (1) | SI0747056T1 (ru) |
| TR (1) | TR199701508T1 (ru) |
| WO (1) | WO1996039141A1 (ru) |
| YU (1) | YU34296A (ru) |
| ZA (1) | ZA964681B (ru) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5558498A (en) * | 1996-11-22 | 1998-06-22 | Akzo Nobel N.V. | Bmp-4 promoter and use thereof in screening of therapeutic agents for the prevention and/or treatment of osteoporosis |
| GB2324726A (en) * | 1997-05-01 | 1998-11-04 | Merck & Co Inc | Combination Therapy for the Treatment of Osteoporosis |
| US6096764A (en) * | 1997-08-21 | 2000-08-01 | Eli Lilly And Company | Methods for inhibiting detrimental side-effects due to GnRH of GnRH agonist administration |
| US7005428B1 (en) | 1998-06-11 | 2006-02-28 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4895715A (en) * | 1988-04-14 | 1990-01-23 | Schering Corporation | Method of treating gynecomastia |
| US5393785A (en) * | 1988-10-31 | 1995-02-28 | Endorecherche, Inc. | Therapeutic antiestrogens |
| US5482949A (en) * | 1993-03-19 | 1996-01-09 | Eli Lilly And Company | Sulfonate derivatives of 3-aroylbenzo[b]thiophenes |
| DE4329344A1 (de) * | 1993-08-27 | 1995-03-02 | Schering Ag | Progesteronantagonistisch- und antiöstrogen wirksame Verbindungen für die Behandlung des Leiomyomata uteri |
-
1996
- 1996-05-30 DK DK96303874T patent/DK0747056T3/da active
- 1996-05-30 ES ES96303874T patent/ES2142545T3/es not_active Expired - Lifetime
- 1996-05-30 PT PT96303874T patent/PT747056E/pt unknown
- 1996-05-30 SI SI9630163T patent/SI0747056T1/xx unknown
- 1996-05-30 DE DE69605600T patent/DE69605600T2/de not_active Expired - Fee Related
- 1996-05-30 EP EP96303874A patent/EP0747056B1/en not_active Expired - Lifetime
- 1996-05-30 AT AT96303874T patent/ATE187643T1/de not_active IP Right Cessation
- 1996-06-05 PE PE1996000409A patent/PE2298A1/es not_active Application Discontinuation
- 1996-06-05 KR KR1019970708978A patent/KR19990022497A/ko not_active Application Discontinuation
- 1996-06-05 ZA ZA9604681A patent/ZA964681B/xx unknown
- 1996-06-05 BR BR9608390A patent/BR9608390A/pt not_active Application Discontinuation
- 1996-06-05 AR ARP960102931A patent/AR003002A1/es not_active Application Discontinuation
- 1996-06-05 CZ CZ973830A patent/CZ383097A3/cs unknown
- 1996-06-05 WO PCT/US1996/008810 patent/WO1996039141A1/en not_active Application Discontinuation
- 1996-06-05 JP JP09501298A patent/JP2001501907A/ja active Pending
- 1996-06-05 HU HU9900854A patent/HUP9900854A3/hu unknown
- 1996-06-05 EA EA199800014A patent/EA199800014A1/ru unknown
- 1996-06-05 CA CA002223174A patent/CA2223174A1/en not_active Abandoned
- 1996-06-05 TR TR97/01508T patent/TR199701508T1/xx unknown
- 1996-06-05 AR ARP960102930A patent/AR003134A1/es not_active Application Discontinuation
- 1996-06-05 YU YU34296A patent/YU34296A/sr unknown
- 1996-06-05 CO CO96029179A patent/CO4700447A1/es unknown
- 1996-06-05 PL PL96323941A patent/PL323941A1/xx unknown
- 1996-06-05 CN CN96195984A patent/CN1239429A/zh active Pending
- 1996-06-05 AU AU59816/96A patent/AU696927B2/en not_active Ceased
- 1996-06-05 IL IL11857396A patent/IL118573A/xx not_active IP Right Cessation
-
1997
- 1997-12-02 NO NO975560A patent/NO975560L/no unknown
-
2000
- 2000-03-03 GR GR20000400555T patent/GR3032863T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR003002A1 (es) | 1998-05-27 |
| HUP9900854A2 (hu) | 1999-08-30 |
| ZA964681B (en) | 1997-12-05 |
| TR199701508T1 (xx) | 1998-03-21 |
| DE69605600D1 (de) | 2000-01-20 |
| PL323941A1 (en) | 1998-04-27 |
| ATE187643T1 (de) | 2000-01-15 |
| EP0747056A2 (en) | 1996-12-11 |
| CN1239429A (zh) | 1999-12-22 |
| NO975560L (no) | 1998-01-26 |
| SI0747056T1 (en) | 2000-06-30 |
| EP0747056B1 (en) | 1999-12-15 |
| BR9608390A (pt) | 1999-05-04 |
| GR3032863T3 (en) | 2000-07-31 |
| WO1996039141A1 (en) | 1996-12-12 |
| AU5981696A (en) | 1996-12-24 |
| EP0747056A3 (en) | 1997-03-05 |
| CA2223174A1 (en) | 1996-12-12 |
| CO4700447A1 (es) | 1998-12-29 |
| DK0747056T3 (da) | 2000-05-01 |
| ES2142545T3 (es) | 2000-04-16 |
| IL118573A0 (en) | 1996-10-16 |
| JP2001501907A (ja) | 2001-02-13 |
| DE69605600T2 (de) | 2000-05-31 |
| CZ383097A3 (cs) | 1998-09-16 |
| AU696927B2 (en) | 1998-09-24 |
| KR19990022497A (ko) | 1999-03-25 |
| PT747056E (pt) | 2000-05-31 |
| NO975560D0 (no) | 1997-12-02 |
| HUP9900854A3 (en) | 2000-03-28 |
| PE2298A1 (es) | 1998-02-28 |
| AR003134A1 (es) | 1998-07-08 |
| IL118573A (en) | 2000-01-31 |
| YU34296A (en) | 1999-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR024060A1 (es) | Nuevos compuestos farmaceuticamente activos | |
| YU61595A (sh) | Nova naftilna jedinjenja, njihovi intermedijeri farmaceutske kompozicije, i postupci za dobijanje tih jedinjenja | |
| EA200500018A1 (ru) | Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения | |
| RU2006134003A (ru) | Серосодержащие соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с | |
| RU94045846A (ru) | Применение производных бензотиофена для ингибирования тромбина | |
| RU2006134005A (ru) | Новые соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с | |
| EA200100983A1 (ru) | Производные 13-метилэритромицина | |
| BR0212346A (pt) | Composto ou um sal farmaceuticamente aceitável, solvato, solvato deste sal ou uma pró-droga do mesmo, processo para a preparação do mesmo, uso deste, método para produzir um efeito inibidor de ibat em um animal de sangue quente, como um humano, em necessidade deste tratamento, e, composição farmacêutica | |
| ES2141957T3 (es) | Uso de raloxifeno y sus analogos para la produccion de un medicamento para el tratamiento de enfermedades virales. | |
| EA200600892A1 (ru) | Новые хинолиновые производные | |
| BG66085B1 (bg) | Фенилаланинови производни | |
| EA199800013A1 (ru) | Способы минимизации остеопороза | |
| LV12291A (lv) | Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai | |
| ES2157314T3 (es) | Derivados triciclicos y su uso en productos farmaceuticos. | |
| DZ1694A1 (fr) | "n-(2-Aminoethyl)-benzothialozones". | |
| EA199700450A1 (ru) | Способы подавления миграции сосудистых гладкомышечных клеток | |
| YU42397A (sh) | Korišćenje raloksifena za pripremu leka | |
| ES2033062T3 (es) | Un procedimiento de preparacion de derivados n-imidazolil y n-imidazolilmetil. | |
| ATE319715T1 (de) | Antikonvulsive pseudofructopyranose sulfamate | |
| EA199800014A1 (ru) | Способы снижения до минимума эффекта остеопороза | |
| ES2131300T3 (es) | Derivados triciclicos y composiciones farmaceuticas que los contienen. | |
| RU97106107A (ru) | Способ минимизации гистеротрофного эффекта тамоксифена и аналогов тамоксифена | |
| ES2128701T3 (es) | Derivados triciclicos y su uso en productos farmaceuticos. | |
| NO971229D0 (no) | Fremgangsmåte for minimalisering av den uterotrofiske effekt av tamoxifen og tamoxifenanaloger | |
| EA199700287A1 (ru) | Бензамиды для лечения нейродегенеративных заболеваний |